Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
ARCHIVE: eXoZymes signifiy a sustainable paradigm shift in chemical production leveraging AI-engineered enzymes
investorvideoARCHIVE
ARCHIVE: eXoZymes signifiy a sustainable paradigm shift in chemical production leveraging AI-engineered enzymesFebruary 12, 2025
ARCHIVE: Rebranding Invizyne to eXoZymes signifies a sustainable paradigm shift in chemical production leveraging AI-engineered enzymes
press releaseinvestorARCHIVE
ARCHIVE: Rebranding Invizyne to eXoZymes signifies a sustainable paradigm shift in chemical production leveraging AI-engineered enzymesFebruary 12, 2025
ARCHIVE: Looking at the rest of 2025 - part 4 of a fireside chat about Invizyne
heltzeninvestorvideoARCHIVE
ARCHIVE: Looking at the rest of 2025 - part 4 of a fireside chat about InvizyneFebruary 11, 2025
ARCHIVE: Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol
press releaseinvestorARCHIVE
ARCHIVE: Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker SymbolFebruary 10, 2025
ARCHIVE: CEO buys IZTC stock
investorARCHIVE
ARCHIVE: CEO buys IZTC stockJanuary 21, 2025
ARCHIVE: Go To Market Strategy - part 3 of a fireside chat about Invizyne
heltzeninvestorvideoARCHIVE
ARCHIVE: Go To Market Strategy - part 3 of a fireside chat about InvizyneJanuary 15, 2025
ARCHIVE: Using AI for Enzyme Engineering - Part 2 of a Fireside Chat About Invizyne
heltzeninvestorvideoARCHIVE
ARCHIVE: Using AI for Enzyme Engineering - Part 2 of a Fireside Chat About InvizyneJanuary 7, 2025
ARCHIVE: Looking back at 2024 - part 1 of a fireside chat about Invizyne
heltzeninvestorvideoARCHIVE
ARCHIVE: Looking back at 2024 - part 1 of a fireside chat about InvizyneDecember 31, 2024
ARCHIVE: Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities
biofuelpress releaseARCHIVE
ARCHIVE: Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel CapabilitiesNovember 19, 2024
ARCHIVE: Invizyne Technologies Announces Closing of Initial Public Offering
press releaseinvestorARCHIVE
ARCHIVE: Invizyne Technologies Announces Closing of Initial Public OfferingNovember 14, 2024
Previous page
Page 8 of 11
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark